Understanding the Benefits & Risks of Corticosteroid Use in Patients With IgAN
This infographic highlights clinical trial results showing mixed efficacy and increased adverse events in patients with IgAN treated with corticosteroids. Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
IgA Nephropathy
Updates in IgA Nephropathy
Learn the latest advancements in the understanding and management of IgA Nephropathy (IgAN) with two expert-led videos sponsored by Otsuka with Professors Brad Rovin, MD (United States) and Jürgen Floege,… Read MoreOn-Demand Webinar: The Four-Hit Hypothesis & The Role Of APRIL In IgA Nephropathy
The goal of this on-demand webinar is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read MoreBreakdown of the MEST-C Score in IgA Nephropathy
This podcast provides an in-depth review of the Oxford MEST-C score, focusing on its practical application in diagnosing and prognosticating IgA Nephropathy. Read MoreRole of the Renal Pathologist in IgA Nephropathy
Through the lens of renal pathology, this webinar will provide insights into the histopathological features that are crucial for accurate diagnosis and risk stratification in IgA Nephropathy, highlighting the significance… Read MoreIgA Nephropathy in Kidney Transplantation
Join us to hear from Dr. Fahad Aziz, Associate Profession of Nephrology, and Transplant Nephrologist at the University of Wisconsin, Madison, to learn more about IgAN in kidney transplantation. Read MoreRisk of Progression to ESKD in IgA Nephropathy
This infographic highlights the risk of progression to ESKD, including in patients traditionally considered low risk. Read MoreOverview of IgAN
This infographic focuses on IgAN diagnosis, prognosis, and disease management strategies. Read MoreAPRIL & the 4-Hit Pathogenic Cascade of IgAN
This infographic highlights the role of APRIL in a pre-hit 1 step that drives the 4-hit cascade.1 References 1. Mathur M, et al. J Clin Med. 2023;12(21):6927. Read MoreMental Health Implications in IgA Nephropathy
Join us for this webinar to learn more about mental health in IgAN and how it impacts patients, caregivers, healthcare providers, as well as related stressors. Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
